RB-1355 and the Evolution of Antitumoral Macrophage Therapy

In the pursuit of more effective cancer treatments, the focus has increasingly shifted toward the innate power of the immune system’s primary defenders. Central to this evolution is RB-1355, a novel therapeutic comprised of autologous macrophages. Derived from a patient’s own circulating monocytes, these cells undergo a sophisticated transformation process, being exposed to a proprietary cytokine and chemokine cocktail known as Macrophage Activation Catalyst for Hyperactivation, or MACH-1. This exposure effectively "repolarizes" the macrophages, shifting them toward a potent antitumoral phenotype.

In an interview with Targeted Oncology, Paolo Strati, MD, associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and presenting author of the trial, breaks down the mechanism of RB-1355.